In8bio
INAB

Common Stock offered 5,127,029 shares by the company

From June 30, 2025 to September 30, 2025 Issuance of common stock, net of issuance costs

From March 31, 2025 to June 30, 2025 Issuance of common stock, net of issuance costs Issuance of common stock upon exercise of Series A&B warrants, net of issuance costs

a reverse stock split at a ratio of 1-for-30

From December 31, 2024 to March 31, 2025 Issuance of common stock, net of issuance costs Issuance of common stock upon exercise of Series C warrants, net of issuance costs

From December 31, 2023 to December 31, 2024 Issuance of common stock, net of issuance costs Issuance of common stock upon exercise of Series A warrants, net of issuance costs Issuance of private placement common stock, net of issuance costs Issuance of private placement warrants, net of issuance costs

On October 4, 2024 the company issued 25,759,595 common shares

From June 30, 2024 to September 30, 2024 Issuance of common stock, net of issuance costs

From March 31, 2024 to June 30, 2024 Issuance of common stock, net of issuance costs Issuance of common stock upon exercise of Series A warrants, net of issuance costs

From December 31, 2022 to December 31, 2023 Issuance of common stock, net of issuance costs of $445 Issuance of private placement common stock, net of issuance costs of $729

From June 30, 2023 to September 30, 2023 Issuance of common stock, net of issuance cost

From March 31, 2023 to June 30, 2023 Issuance of common stock, net of issuance cost

From December 31, 2022 to March 31, 2023 Issuance of common stock, net of issuance cost

From December 31, 2021 to December 31, 2022 Issuance of common stock, net of issuance costs of $919 Stock options exercises

From June 30, 2022 to September 30, 2022 Issuance of common stock, net of issuance costs

Today announced that the underwriter of its previously announced underwritten public offering of common stock which closed on August 16, 2022 has partially exercised its option to purchase an additional 268,949 shares at the public offering price of $1.90 per share, resulting in additional gross proceeds of approximately $0.5 million. After giving effect to the partial exercise of the option to purchase additional shares, the total number of shares sold by IN8bio in the public offering increased to 5,663,686 shares and gross proceeds increased to approximately $10.75 million.

1.Common stock to be offered 5,394,737 shares 2.The number of shares of the company common stock to be outstanding after this offering is based on 18,812,267 shares of common stock outstanding as of March 31, 2022

From December 31, 2020 to December 31, 2021 Issuance of common stock – as a result of IPO, net of issuance costs of $7,685 Conversion of convertible preferred stock to common stock upon closing of IPO Stock options exercises

1.Common stock to be offered 4,000,000 shares 2.The number of shares of common stock to be outstanding after this offering is based on 14,754,553 shares of common stock outstanding as of March 31, 2021